Cerus (CERS) Corporation announced it has been awarded an additional $7.2M contract amendment by the U.S. Department of Defense Industrial Base Analysis and Sustainment program for the development of lyophilized INTERCEPT Fibrinogen Complex, or IFC, to treat bleeding due to trauma. The additional funding will support CRYO-FIRST, a randomized study comparing the use of pre-thawed IFC to conventional cryoprecipitated antihemophilic factor in trauma-associated hemorrhagic shock patients. This is additive to the approximately $18M currently provided under Cerus’ contract with the DoD.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERS: